TREATMENT APPROACHES
VMAT2 Inhibitor Pharmacology Animation
View an animated video highlighting key pharmacologic differences between the vesicular monoamine transporter 2 (VMAT2) inhibitors approved for the treatment of tardive dyskinesia (TD).
Empty space, drag to resize
Write your awesome label here.
MED-MSL-VBZ-US-0002


Up Next
VMAT2 Inhibitors: Clinical Pharmacology
This advanced course is designed for learners who want to deepen their understanding of treatments for tardive dyskinesia. The module focuses on the clinical pharmacology of VMAT2 inhibitors, exploring their mechanisms of action, pharmacologic properties, and relevance to dopamine receptor–blocking agent (DRBA)–induced movement disorders.
Your Resources on Tardive Dyskinesia and Other DIMDs
These
free educational resources are
sponsored and developed by
Neurocrine Biosciences, Inc.
Media Platforms

TD Dialogues® Podcast
Hear from experts in insightful conversations as they discuss the challenges of recognizing TD and share real-world strategies to effectively support patients
in managing symptoms.

Neurocrine Medical: Brave Science™ YouTube Channel
This channel features educational videos designed
to further understanding of TD, including content on the proposed mechanism of disease in TD and differentiating TD from drug-induced parkinsonism.
This educational
content was sponsored and developed
by Neurocrine Biosciences, Inc. This
non-CME program is intended to
provide general information about
drug-induced movement disorders and
not medical advice for any particular
patient.
LearnWorlds Privacy Policy | Terms & Conditions | Cookie Policy
Neurocrine Privacy Policy

Copyright © 2026
MED-MI-TD-US-0276


